and sunitinib lead reduced tumor growth and SUVmax which indicates suppressed GLUT1 expression. CONCLUSIONS: Our results indicate that TKI treatment induces GLUT1 expression and metabolic alterations which will lead cell proliferations on RCC cells. Blockade of IL-6 pathway which induces inflammation amplifier by NFkB activation is crucial for RCC treatment.
INTRODUCTION AND OBJECTIVES: Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) demonstrate the significant efficacy for advanced clear cell renal cell carcinoma (ccRCC), however, it eventually becomes resistant to VEGFR-TKIs during the treatment. So far, the mechanisms for the resistance to VEGFR-TKIs remain to be fully elucidated. Previously we have identified the gene set which could predict poor prognosis of ccRCC patients (Takahashi M et.al., Proc Natl Acad Sci U S A., 98: 9754, 2001 ). We examined whether the insulin receptor (INSR) expression in the gene set may correlate with the resistance to VEGFR-TKIs.
METHODS: The INSR expression was examined immunohistochemically in the nephrectomy specimens of the RCC patients (n¼33) who then received axitinib as the VEGFR-TKI and correlated with their survival outcome. We compared the INSR expression of the nephrectomy or metastasectomy specimens before and after the administration of VEGFR-TKIs in 5 cases. The INSR expression of the human renal glomerular endothelial cells (HGEC) was compared before and after the administration of axitinib by Western blotting. In addition, we established patient derived Xenograft model (PDX) of ccRCC. Tumors of PDX were resected when it regrew and showed the resistance for axitinib and the INSR expression was compared before and after the treatment by Western blotting.
RESULTS: The INSR was expressed at the vessels surrounding tumor cells. Progression-free survival (PFS) was significantly shorter in the INSR-negative group than in the INSR-positive group. Multivariate analysis revealed that the INSR expression was the significantly independent predictor of PFS. In the specimens resected after VEGFR-TKI, the INSR expression was more frequently decreased. As the concentration of axitinib increased, the INSR expression in the HGEC was decreased. The tumors of PDX that were resected after demonstrating the resistance to axitinib had the decreased INSR expression.
CONCLUSIONS: The decreased INSR expression could be correlated with the resistance to VEGFR-TKI and its expression may be useful in selecting appropriate drugs for advanced ccRCC patients. METHODS: The ccRCC cell lines Caki-1 and Caki-2 were continuously exposed to increasing concentrations of sunitinib for 6-8 months until acquiring resistance. These cells were termed Caki-1/SR and Caki-2/SR. Cell viability was assessed using MTT assays. Exosomes were harvested and characterized by nanoparticle tracking analysis. Changes in the integrin expression profiles and various signaling pathways were determined using Western blot analysis of cell and exosome lysates. Alterations in adhesion were established using standard in vitro assays. Integrin inside-out signaling pathway array plates were used to compare mRNA expression levels.
RESULTS: Integrin expression levels were found to be variable among parental and resistant ccRCC cell lines. Gene expression analysis revealed reduced levels of COL1A1 and COL1A2, components of type I collagen, in Caki-1/SR. Western blot analysis demonstrated a decrease in beta-3 integrin protein levels in Caki-1/SR compared to Caki-1. Adhesion analysis determined Caki-1/SR cells exhibited decreased adhesion to several extracellular matrices. Conversely, Caki-2/SR cells demonstrated an increase in beta-1 and beta-3 integrins compared to Caki-2. Altered levels of beta-1 and beta-3 integrins were observed in exosomes released by both resistant cell lines. Initial protein studies suggest downstream signaling pathways affected by the change in levels of integrin expression include FAK and NF-kB. CONCLUSIONS: Our findings suggest sunitinib resistance in Caki-1 and Caki-2 ccRCC cells is associated with integrin expression. Beta-1 and Beta-3 integrin levels correlated with resistance in Caki-2 cells. Exosomal integrin levels were altered in sunitinib resistant cells. Continued investigation into the role of integrins in sunitinib resistant cell lines, including the effect of variable integrin profiles on downstream signaling pathways and their transference via exosomes, will improve understanding of TKI resistance in ccRCC.
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